Page last updated: 2024-11-03

probenecid and Cancer of Skin

probenecid has been researched along with Cancer of Skin in 2 studies

Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Hanouna, G1
Tang, E1
Perez, J1
Vandermeersch, S1
Haymann, JP1
Baud, L1
Letavernier, E1
Gupta, S1
Aggarwal, S1
Nakamura, S1

Other Studies

2 other studies available for probenecid and Cancer of Skin

ArticleYear
Preventing Calpain Externalization by Reducing ABCA1 Activity with Probenecid Limits Melanoma Angiogenesis and Development.
    The Journal of investigative dermatology, 2020, Volume: 140, Issue:2

    Topics: Animals; ATP Binding Cassette Transporter 1; Calcium-Binding Proteins; Calpain; Cell Line, Tumor; Ce

2020
A possible role of multidrug resistance-associated protein (MRP) in basic fibroblast growth factor secretion by AIDS-associated Kaposi's sarcoma cells: a survival molecule?
    Journal of clinical immunology, 1998, Volume: 18, Issue:4

    Topics: AIDS-Related Opportunistic Infections; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Mem

1998